Webdisclosure.com

SANOFI-AVENTIS (EPA:SAN)

20/05/2022 21:15

Press Release: FDA approves Dupixent® (dupilumab) as first treatment for adults and children aged 12 and older with eosinophilic esophagitis

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

15/05/2022 09:30

Press Release: Sarclisa® (isatuximab) combination provides unprecedented median progression free survival in patients with relapsed multiple myeloma receiving a proteasome inhibitor therapy

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

11/05/2022 08:00

Press Release: New nirsevimab data analyses reinforce efficacy against RSV

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

04/05/2022 12:00

Press Release: Foundation S: Sanofi’s new philanthropic spearhead

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/04/2022 20:28

Sanofi: Information concerning the total number of voting rights and shares – March 2022

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/04/2022 12:47

Press Release: Sanofi teams up with McLaren Racing to accelerate industrial excellence

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

04/04/2022 12:00

Press Release: Sanofi launches first-in-pharma Diversity, Equity & Inclusion Board

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

29/03/2022 03:00

Press Release: Sanofi continues on path to industry leadership in Immunology with Dupixent® (dupilumab) as key driver

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

28/03/2022 09:00

Press Release: Xenpozyme® (olipudase alfa) approved in Japan, first and only approved therapy indicated to treat acid sphingomyelinase deficiency

Voir tous les communiqués de SANOFI-AVENTIS

SANOFI-AVENTIS (EPA:SAN)

26/03/2022 17:45

Sanofi: Information concerning the total number of voting rights and shares – February 2022

Voir tous les communiqués de SANOFI-AVENTIS

«
1
2
3
4
5
6
7
8
9
10